

# HLA-DQ (B-K27): sc-65320

## BACKGROUND

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4<sup>+</sup> helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC II- $\alpha\beta$  dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, DQ, DP and DR) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. The  $\alpha$  one chain of HLA-DQ1 class II molecule (Ia antigen) complex can bind peptides and present them to CD4<sup>+</sup> T lymphocytes.

## REFERENCES

1. Corte, G., Calabi, F., Damiani, G., Bargellesi, A., Tosi, R., Sorrentino, R. 1981. Human Ia molecules carrying DC1 determinants differ in both  $\alpha$ - and  $\beta$ -subunits from Ia molecules carrying DR determinants. *Nature* 292: 357-360.
2. Bodmer, J.G. and Bodmer, W.F. 1984. Monoclonal antibodies to HLA determinants. *Br. Med. Bull.* 40: 267-275.
3. Horejsi, V., Nemeč, M., Angelisova, P., Kristofova, H., Gorga, J.C. and Hilgert, I. 1986. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. *Tissue Antigens* 28: 288-297.
4. Momburg, F., Herrmann, B., Moldenhauer, G. and Moller, P. 1987. B cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain. *Int. J. Cancer* 40: 598-603.
5. Kropshofer, H., Vogt, A.B., Thery, C., Armandola, E.A., Li, B.C., Moldenhauer, G., Amigorena, S. and Hammerling, G.J. 1998. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. *EMBO J.* 17: 2971-2981.
6. Siegmund, T., Donner, H., Braun, J., Usadel, K.H. and Badenhoop, K. 1999. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus. *Tissue Antigens* 54: 291-294.
7. Toussiro, E., Sauvageot, C., Chabod, J., Ferrand, C., Tiberghien, P. and Wendling, D. 2000. The association of HLA-DM genes with rheumatoid arthritis in Eastern France. *Hum. Immunol.* 61: 303-308.
8. Brunet, A., Samaan, A., Deshaies, F., Kindt, T.J. and Thibodeau, J. 2000. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DQ $\beta$ . *J. Biol. Chem.* 275: 37062-37071.
9. Doebele, C.R., Busch, R., Scott, M.H., Pashine, A. and Mellins, D.E. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. *Immunity* 13: 517-527.

## CHROMOSOMAL LOCATION

Genetic locus: HLA-DQA1/HLA-DQA2/HLA-DQB1/HLA-DQB2 (human) mapping to 6p21.3.

## SOURCE

HLA-DQ (B-K27) is a mouse monoclonal antibody raised against T4 + CTL clone HG-38.

## PRODUCT

Each vial contains 100  $\mu$ g IgG<sub>2a</sub> in 1.0 ml of PBS with < 0.1% sodium azide, 0.1% gelatin and 1% stabilizer protein.

## APPLICATIONS

HLA-DQ (B-K27) is recommended for detection of HLA-DQ of human origin by immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)] and flow cytometry (1  $\mu$ g per 1 x 10<sup>6</sup> cells).

Molecular Weight of HLA-DQ: 29 kDa.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.